Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Buy | Strong Buy | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Completed Patterns | |||||
Tri-Star Bearish | 30 | 1 | Apr 19, 2024 19:00 | ||
Tri-Star Bearish | 15 | 2 | Apr 19, 2024 19:15 | ||
Bullish Engulfing | 1W | 3 | Mar 24, 2024 | ||
Bullish Engulfing | 1H | 4 | Apr 19, 2024 13:00 | ||
Three Outside Down | 1M | 5 | Nov 23 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 166.42 | 0.00 | 0.00 | 5,056,678 | +1.07% | USD | |||
London | 165.35 | 156.76 | 173.26 | 12,995 | -0.46% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,819.05 | 2,805.35 | 2,859.99 | 0 | +0.00% | MXN | |||
Milan | 154.68 | 0.00 | 0.00 | 81 | -0.86% | EUR | |||
TradeGate | 155.60 | 156.02 | 156.36 | 592 | +0.58% | EUR | |||
Frankfurt | 153.28 | 155.90 | 156.38 | 0 | -0.09% | EUR | |||
B3 | 54.08 | 52.98 | 55.90 | 68 | -0.13% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Rolls-Royce Holdings | 395.50 | 399.00 | 391.20 | -7.00 | -1.74% | 40.91M | 19/04 | ||
IAG | 169.50 | 170.10 | 162.15 | -0.30 | -0.18% | 27.55M | 19/04 | ||
Barclays | 185.84 | 185.90 | 181.50 | +1.86 | +1.01% | 55.13M | 19/04 | ||
Avacta Group | 48.50 | 48.50 | 46.28 | +0.50 | +1.04% | 2.98M | 19/04 | ||
EasyJet | 535.20 | 536.00 | 514.57 | +5.20 | +0.98% | 3.30M | 19/04 | ||
Lloyds Banking | 50.92 | 51.08 | 50.20 | -0.08 | -0.16% | 115.16M | 19/04 | ||
HSBC | 646.20 | 647.60 | 633.80 | +1.60 | +0.25% | 40.81M | 19/04 | ||
Helium One | 1.3780 | 1.4825 | 1.2500 | +0.1030 | +8.08% | 69.85M | 19/04 | ||
BP | 514.90 | 516.01 | 504.60 | +2.50 | +0.49% | 42.63M | |||
Vodafone Group PLC | 67.000 | 67.100 | 65.780 | +0.620 | +0.93% | 58.54M | 19/04 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review